Seki Yoichi, Takemura Ryo, Sutoh Chihiro, Noguchi Remi, Okamoto Yoko, Ohira Ikuyo, Nagata Shinobu, Shimizu Eiji
Cognitive Behavioral Therapy Center, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, , 260-8677, Chiba, Japan.
Clinical and Translational Research Center, Keio University Hospital, 35 Shinanomachi, Sinjuku-ku, Tokyo, 160-8582, Japan.
BMC Psychiatry. 2025 Sep 24;25(1):861. doi: 10.1186/s12888-025-07320-2.
Additional treatment options for pharmacotherapy-refractive patients with panic disorder are needed. Given the difficulty in accessing professional cognitive behavioral therapy in real-world clinical settings, pharmacotherapy remains the typical treatment in patients with panic disorder. However, some patients with panic disorder remain symptomatic despite pharmacotherapy. In this study, to highlight next-step treatment options for patients with panic disorder, we aimed to assess the efficacy of videoconference-based cognitive behavioral therapy for patients with panic disorder who remained symptomatic despite initial pharmacological treatment. To this end, we evaluated the effectiveness of videoconference-based cognitive behavioral therapy for patients as an adjunct to usual care.
Symptomatic patients with panic disorder following primary pharmacotherapy were randomly assigned to videoconference-based cognitive behavioral therapy or usual care-only groups. The primary outcomes were a reduction in symptomatology assessed at 8 and 16 weeks, using the Panic Disorder Severity Scale. We calculated the 95% confidence intervals (CIs) of the mean with an unknown variance.
Thirty participants were included in this study. After 16 weeks, the adjusted mean changes in Panic Disorder Severity Scale score from baseline were - 7.92 and 0.75 in the videoconference-based cognitive behavioral therapy (n = 15) and usual care (n = 15) groups, respectively, with a between-group difference of - 8.67 (95% CI: -11.80 to - 5.54; P < .0001). A considerable proportion of patients in the videoconference-based cognitive behavioral therapy group achieved a positive response at week 16 (80% vs. 6.7%; P < .001) and demonstrated a higher remission rate (66.7% vs. 0.0%; P < .001) than that in the usual care group.
Thus, videoconference-based cognitive behavioral therapy is an effective treatment for patients with panic disorder who remain symptomatic following pharmacotherapy. The results suggest that videoconference-based cognitive behavioral therapy, which can be used at home, may be effective for patients with panic disorder or chronic panic disorder who have difficulty accessing cognitive behavioral therapy.
The study was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN000029987) on Nov 20, 2017.
对于药物治疗无效的惊恐障碍患者,需要更多的治疗选择。鉴于在现实临床环境中难以获得专业的认知行为疗法,药物治疗仍是惊恐障碍患者的典型治疗方法。然而,一些惊恐障碍患者尽管接受了药物治疗仍有症状。在本研究中,为了突出惊恐障碍患者的下一步治疗选择,我们旨在评估基于视频会议的认知行为疗法对尽管接受了初始药物治疗仍有症状的惊恐障碍患者的疗效。为此,我们评估了基于视频会议的认知行为疗法作为常规护理辅助手段对患者的有效性。
原发性药物治疗后有症状的惊恐障碍患者被随机分配到基于视频会议的认知行为治疗组或仅接受常规护理组。主要结局是使用惊恐障碍严重程度量表在第8周和第16周评估的症状减轻情况。我们计算了方差未知时均值的95%置信区间(CI)。
本研究纳入了30名参与者。16周后,基于视频会议的认知行为治疗组(n = 15)和常规护理组(n = 15)中,惊恐障碍严重程度量表评分从基线的调整后平均变化分别为-7.92和0.75,组间差异为-8.67(95% CI:-11.80至-5.54;P <.0001)。基于视频会议的认知行为治疗组中有相当比例的患者在第16周获得了阳性反应(80%对6.7%;P <.001),并且缓解率高于常规护理组(66.7%对0.0%;P <.001)。
因此,基于视频会议的认知行为疗法是对药物治疗后仍有症状的惊恐障碍患者的一种有效治疗方法。结果表明,可在家中使用的基于视频会议的认知行为疗法可能对难以获得认知行为疗法的惊恐障碍或慢性惊恐障碍患者有效。
该研究于2017年11月20日在大学医院医学信息网络临床试验注册中心(UMIN000029987)注册。